167 related articles for article (PubMed ID: 37368350)
41. Epidemiology and Determinants of Survival for Primary Intestinal Non-Hodgkin Lymphoma: A Population-Based Study.
Singh V; Gor D; Gupta V; Jacob A; Du D; Eltoukhy H; Meghal T
World J Oncol; 2022 Aug; 13(4):159-171. PubMed ID: 36128593
[TBL] [Abstract][Full Text] [Related]
42. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
43. New REAL clinical entities.
Fisher RI; Miller TP; Grogan TM
Cancer J Sci Am; 1998 Jul; 4 Suppl 2():S5-12. PubMed ID: 9672769
[TBL] [Abstract][Full Text] [Related]
44. Diffuse large B-cell non-Hodgkin lymphomas: the clinical relevance of histological subclassification.
Baars JW; de Jong D; Willemse EM; Gras L; Dalesio O; v Heerde P; Huygens PC; vd Lelie H; Kr vd Borne AE
Br J Cancer; 1999 Apr; 79(11-12):1770-6. PubMed ID: 10206291
[TBL] [Abstract][Full Text] [Related]
45. Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
Truelove E; Fox C; Robinson S; Pearce R; Perry J; Kirkland K; McQuaker G; Pagliuca A; Johnson P; Russell N; Cook G;
Biol Blood Marrow Transplant; 2015 Mar; 21(3):483-8. PubMed ID: 25490180
[TBL] [Abstract][Full Text] [Related]
46. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
47. Primary extra nodal non Hodgkin lymphoma: a 5 year retrospective analysis.
Padhi S; Paul TR; Challa S; Prayaga AK; Rajappa S; Raghunadharao D; Sarangi R
Asian Pac J Cancer Prev; 2012; 13(10):4889-95. PubMed ID: 23244076
[TBL] [Abstract][Full Text] [Related]
48. Treatment of T-cell non-Hodgkin's lymphoma.
Evens AM; Gartenhaus RB
Curr Treat Options Oncol; 2004 Aug; 5(4):289-303. PubMed ID: 15233906
[TBL] [Abstract][Full Text] [Related]
49. Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network.
LaCasce AS; Kho ME; Friedberg JW; Niland JC; Abel GA; Rodriguez MA; Czuczman MS; Millenson MM; Zelenetz AD; Weeks JC
J Clin Oncol; 2008 Nov; 26(31):5107-12. PubMed ID: 18768434
[TBL] [Abstract][Full Text] [Related]
50. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
Tilly H; Morschhauser F; Bartlett NL; Mehta A; Salles G; Haioun C; Munoz J; Chen AI; Kolibaba K; Lu D; Yan M; Penuel E; Hirata J; Lee C; Sharman JP
Lancet Oncol; 2019 Jul; 20(7):998-1010. PubMed ID: 31101489
[TBL] [Abstract][Full Text] [Related]
51. [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
Qin Y; Shi YK; He XH; Yang JL; Yang S; Yu YX; Li B; Wang QL; Zhou LQ; Sun Y
Ai Zheng; 2006 Apr; 25(4):481-5. PubMed ID: 16613685
[TBL] [Abstract][Full Text] [Related]
52. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
53. Chronic viral hepatitis, HIV infection and Non-Hodgkin lymphomas in West Africa, a case-control study.
Jaquet A; Boni SP; Boidy K; Tine J; Tchounga B; Touré SA; Koffi JJ; Dial C; Monnereau A; Diomande I; Tanon A; Seydi M; Dabis F; Diop S; Koffi G;
Int J Cancer; 2021 Oct; 149(8):1536-1543. PubMed ID: 34124779
[TBL] [Abstract][Full Text] [Related]
54. Lymphomas in sub-Saharan Africa--what can we learn and how can we help in improving diagnosis, managing patients and fostering translational research?
Naresh KN; Raphael M; Ayers L; Hurwitz N; Calbi V; Rogena E; Sayed S; Sherman O; Ibrahim HA; Lazzi S; Mourmouras V; Rince P; Githanga J; Byakika B; Moshi E; Durosinmi M; Olasode BJ; Oluwasola OA; Akang EE; Akenòva Y; Adde M; Magrath I; Leoncini L
Br J Haematol; 2011 Sep; 154(6):696-703. PubMed ID: 21707579
[TBL] [Abstract][Full Text] [Related]
55. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
56. Adherence to guidelines-recommended diagnostic testing was associated with overall survival in patients with diffuse large B-cell lymphoma after rituximab-based treatment: an observational cohort study.
Yang F; Zhang J; Abraham A; Yan JT; Hammer RD; Prime MS
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3691-3700. PubMed ID: 35974175
[TBL] [Abstract][Full Text] [Related]
57. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.
Zhou Z; Sehn LH; Rademaker AW; Gordon LI; Lacasce AS; Crosby-Thompson A; Vanderplas A; Zelenetz AD; Abel GA; Rodriguez MA; Nademanee A; Kaminski MS; Czuczman MS; Millenson M; Niland J; Gascoyne RD; Connors JM; Friedberg JW; Winter JN
Blood; 2014 Feb; 123(6):837-42. PubMed ID: 24264230
[TBL] [Abstract][Full Text] [Related]
58. Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL).
Kim SJ; Choi CW; Mun YC; Oh SY; Kang HJ; Lee SI; Won JH; Kim MK; Kwon JH; Kim JS; Kwak JY; Kwon JM; Hwang IG; Kim HJ; Lee JH; Oh S; Park KW; Suh C; Kim WS
BMC Cancer; 2011 Jul; 11():321. PubMed ID: 21798075
[TBL] [Abstract][Full Text] [Related]
59. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011.
Al-Hamadani M; Habermann TM; Cerhan JR; Macon WR; Maurer MJ; Go RS
Am J Hematol; 2015 Sep; 90(9):790-5. PubMed ID: 26096944
[TBL] [Abstract][Full Text] [Related]
60. Non-Hodgkin lymphoma in Southern Africa: review of 487 cases from The International Non-Hodgkin Lymphoma Classification Project.
Perry AM; Perner Y; Diebold J; Nathwani BN; MacLennan KA; Müller-Hermelink HK; Bast M; Boilesen E; Armitage JO; Weisenburger DD
Br J Haematol; 2016 Mar; 172(5):716-23. PubMed ID: 26898194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
